The Prognostic Value of Plasma Galectin-3 in Chronic Heart Failure Patients Is Maintained when Treated with Mineralocorticoid Receptor Antagonists

Koukoui, Francois; Desmoulin, Franck; Galinier, Michel; Barutaut, Manon; Caubere, Celine; Evaristi, Maria Francesca; Murat, Gurbuz; De Boer, Rudolf; Berry, Matthieu; Smih, Fatima

Published in:
PLoS ONE

DOI:
10.1371/journal.pone.0119160

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2015

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Koukoui, F., Desmoulin, F., Galinier, M., Barutaut, M., Caubere, C., Evaristi, M. F., Murat, G., De Boer, R., Berry, M., Smih, F., & Rouet, P. (2015). The Prognostic Value of Plasma Galectin-3 in Chronic Heart Failure Patients Is Maintained when Treated with Mineralocorticoid Receptor Antagonists. PLoS ONE, 10(3), [e0119160]. https://doi.org/10.1371/journal.pone.0119160
RESEARCH ARTICLE

The Prognostic Value of Plasma Galectin-3 in Chronic Heart Failure Patients Is Maintained when Treated with Mineralocorticoid Receptor Antagonists

François Koukoui¹, Franck Desmoulin¹, Michel Galinier¹,², Manon Barutaut¹, Celine Caubère¹, Maria Francesca Evaristi¹, Gurbuz Murat¹,², Rudolf De Boer³, Matthieu Berry¹,², Fatima Smih¹, Philippe Rouet¹*¹

¹ INSERM I2MC, UMR 1048, Université UPS, Equipe, Obésité et insuffisance cardiaque: approches moléculaires et cliniques, F-31432 Toulouse, France, ² CHU de Rangueil, Service de Cardiologie A, F-31432 Toulouse, France, ³ Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

* philippe.rouet@inserm.fr

Abstract

Objective

Galectin-3 (Gal-3) is considered as a myocardial fibrosis biomarker with prognostic value in heart failure (HF). Since aldosterone is a neurohormone with established fibrotic properties, we aimed to investigate if mineralocorticoid receptor antagonists (MRAs) would modulate the prognostic value of Gal-3.

Methods

The IBLOMAVED cohort comprised 427 eligible chronic HF patients (CHF) with echocardiography and heart failure biomarkers assessments (BNP). After propensity score matching CHF patients for cardiovascular risk factors, to form balanced groups, Gal-3 levels were measured at baseline in plasma from patients treated with MRAs (MRA-Plus, n=101) or not (MRA-Neg, n=101). The primary end point was all-cause mortality with a follow-up of 3 years.

Results

Gal-3 in plasma from these patients were similar with median values of 14.0 ng/mL [IQR, 9.9–19.3] and 14.4 ng/mL [IQR, 12.3–19.8] (P = 0.132) in MRA-Neg and MRA-Plus, respectively. Patients with Gal-3 ≤17.8 ng/mL had an HR of 1 (reference group) and 1.5 [0.4–5.7] in MRA-Neg and MRA-Plus, respectively (p=0.509). Patients with Gal-3 ≥17.8 ng/mL had an HR of 7.4 [2.2–24.6] and 9.0 [2.9–27.8] in MRA-Plus and MRA-Neg, respectively (p=0.539) and a median survival time of 2.4 years [95%CI,1.8–2.4]. Multivariate Cox proportional hazard analysis confirmed that MRA and the interaction term between MRA treatment and Gal-3 ≥17.8 ng/mL were not factors associated with survival.
Conclusions

MRA treatment did not impair the prognostic value of Gal-3 assessed with a 17.8 ng/mL cut off. Gal-3 levels maintained its strong prognostic value in CHF also in patients treated with MRAs. The significance of the observed lack of an interaction between Gal-3 and treatment effect of MRAs remains to be elucidated.

Introduction

Galectin-3 (Gal-3), a member of the family of beta-galactoside-binding lectins, is a 30 kDa glycoprotein with a carbohydrate recognition domain of 130 amino acids that plays a role in many biological processes, including fibrosis [1–3]. Gal-3 provides a link between inflammation and fibrosis. Macrophage-derived Gal-3 was first suggested to be an important mediator in cardiac fibrosis by inducing cardiac fibroblast proliferation and collagen deposition resulting in HF development and progression [4]. Gal-3 was proposed as a biomarker of heart fibrosis that could predict outcome of heart failure (HF) [5]. In several cohorts of acute HF [6, 7] and chronic HF [8], Gal-3 was shown to be a powerful predictor of mortality. In most studies, Gal-3 had independent prognostic value when corrected for common risk factors such as age, gender and (NT-pro)BNP. Further, elevated Gal-3 in subjects from the general population has been associated with increased mortality [9, 10] and new-onset HF [10]. Recently, Gal-3 was approved by the US Food and Drug Administration as a new biomarker for HF risk stratification and has received a Class IIb recommendation for additive risk stratification in AHA/ACC guidelines [11].

Gal-3 has established interaction with specific pathophysiology in the HF syndrome. For instance, a strong interaction with kidney function seems to exist [12]. Further, in HF patients, Gal-3 levels have been shown to be significantly correlated with serum markers of cardiac extracellular matrix turnover [13]. Experimental evidences clearly link Gal-3 to fibrosis in the heart [14], but also renal [15], liver [16], and lung fibrosis [17].

Aldosterone is a central player in fibrosis [18]. Gal-3 has been shown to mediate the aldosterone-induced fibrosis response [19]. Therefore, we aimed to evaluate if the prognostic value of Gal-3 in chronic heart failure patients, either treated or not treated by mineralocorticoid receptor antagonists (MRAs), would be different. MRAs are recommended in the ESC and AHA/ACC guidelines as an additional therapeutic option to improve outcomes in patients with HF and reduced ejection fraction [11, 20]. The anti-fibrotic action of MRAs has been proposed as one of the mechanisms linked to the clinical benefit of aldosterone blockade [21]. A subanalysis of the RALES study showed that high baseline serum levels of markers of matrix turnover were significantly associated with poor outcome, and these markers were amenable to spironolactone therapy [22]. Given the intimate relation between aldosterone, fibrosis, and Gal-3, and the differential effects of MRAs in patients with active fibrogenesis, we hypothesized that the predictive value of Gal-3 in HF patients may be influenced by the use of MRAs. A recent subanalysis from the HF-ACTION study, however, showed no differential response of MRAs in patients with Gal-3 below or above the FDA-cleared cutpoint of 17.8 ng/mL [23]. Because this study was limited to the pre-specified inclusion/exclusion criteria of the HF-ACTION study, to date, an interaction between effects of anti-aldosterone treatment and Gal-3 has not been definitely demonstrated in HF patients. Our objective was to investigate the effect of MRAs on the prognostic value of Gal-3 in a contemporary cohort of chronic HF patients routinely seen at a University Hospital in France.
Patients and Methods

Ethics statement

The IBLOMAVED study was registered in a clinical database (ClinicalTrials.gov NCT01024049) and conform to the ethical guidelines of the 1975 Declaration of Helsinki. The protocol was approved by the institution’s human research (COSSEC) and regional ethics committee (Comite de Protection des Personnes (CPP) # DC 2008–452). Written informed consent was obtained from all participants and/or their legally authorized representatives.

Study design

This is a retrospective investigation of interaction between MRA treatment and the prognostic value of Gal-3 in a subset of CHF patients from the IBLOMAVED study [24]. The IBLOMAVED cohort comprised 686 patients admitted between July 2007 and May 2013 to the cardiology department at Rangueil Hospital, Toulouse, France. Inclusion criteria required absence of stroke within the last 6 months, acute liver failure within the last 6 months or known chronic hepatic failure (alanine aminotransferase or aspartate amino transferase 5 times the upper regular limits), history for alcohol abuse or drug addiction, cancer or a diagnosis of cancer within 5 years, history of recent or current drug or alcohol abuse, participation in any clinical trial within 30 days prior to admission, hematological pathology (myelodegenerative syndrome, severe anemia (Hb, 8 g / 100 mL) or severe neutropenia (neutrophile count, 1000 cells /mL), thrombocytopenia (platelet count,7500 plts/mL). Baseline demographic data, admission vital signs, clinical history, assessment of cardiovascular risk factors and admission medication were recorded. Biochemical data including BNP levels were obtained at admission. Venous blood samples were obtained during the morning within 24 hours following admission. In this cohort, 427 patients had a medical history of HF at admission. This cohort comprised patients from all AHA/ACC HF classification groups to provide a wide spectrum of patients for HF biomarkers studies. All the 686 patients underwent transthoracic echocardiography for left ventricular ejection fraction (LVEF) assessment. We used a threshold value of LVEF < 45% to select stable systolic chronic heart failure (CHF) patients (n = 427). Because of the multivariate filtering (propensity score), patients with missing data were discarded (n = 74). Patients were sorted into two groups: treated by mineralocorticoid receptor antagonists (MRA-Plus; n = 127) or not treated with this drug (MRA-Neg; n = 230). Finally, 101 patients were selected in each group by the propensity score matching method.

Primary end point

The primary end point was all-cause mortality during follow-up.

Measurement of galectin-3

Galectin-3 (Gal-3) was measured at baseline using an automated immunoassay on the VIDAS analyzer (bioMérieux, Marcy l’Etoile, France). The VIDAS Galectin-3 kit quantitatively measures the concentration of human galectin-3 levels in EDTA plasma. This assay has a measuring range of 3.3 to 100 ng/mL, high repeatability (CV about 1%) and reproducibility (CV about 5%), without cross-reactivity with collagens or other members of the galectin family. Commonly used HF medication does not interfere with the assay.

Statistical analysis

Analyses were performed using Statistical R (version 3.0.1; http://www.r-project.org) or Medcalc (version 12.7.7; Medcalc Software bvba, Ostend, Belgium). Continuous variables were
expressed as means ± standard deviation for normally distributed data or as medians with 95% confidence interval. Propensity scores were generated from logistic regression analysis (MatchIt package version 2.4.21)\cite{25} with MRA treatment as dependent variable and included age, gender, obesity, diabetes, arterial hypertension (AHT), dyslipidemia, ischemic cardiomyopathy (ICM), left ventricular ejection fraction (LVEF), heart rate (HR), blood creatinine concentration (Creat) as predictors. Pairs of MRA-Neg and MRA-Plus patients were formed with propensity scores differing by at most 0.25 of the standard deviation of the logit of the propensity score \cite{26}. Non parametric Mann–Whitney rank sum test and Chi-square test were used for statistical testing of continuous and categorical variables, respectively. Survival curves were constructed using the Kaplan-Meier method and compared with the log-rank test. Patients were categorized based on a Gal-3 threshold value of 17.8 ng/mL \cite{27}. Additional categorization was made based on MRA treatment and patients not using MRAs with Gal-3 ≤ 17.8 ng/mL constituted the reference group (HR = 1.0). Univariate Cox regression was applied to evaluate the hazard ratio of covariates adjusted for age and gender. Multivariate Cox proportional hazards models 1 to 3 were performed with variables that obtained a \textit{p}<0.2 as result of the univariate analysis. Stepwise regression was performed with the variable entered if its associated significance level was less than \textit{P}<0.1 and removed if its associated significance level was greater than \textit{P}>0.2 in the regression model.

**Results**

In the CHF subset of the IBLOMAVED cohort, about one third of the patients were treated by MRAs (123/353). The propensity score matching method was used to balance demographic and clinical criteria between MRA-Neg and MRA-Plus patients (Table 1). After matching, the selected 101 pairs of MRA-Neg and MRA-Plus patients presented similar characteristics for the matched variables. Treatments with beta blockers, ACE inhibitors and loop diuretics (Furosemide) were more frequently used in MRA-Plus patients. BNP measured at admission were similar in both groups (Table 1). Gal-3 retrospectively measured in plasma of these groups of patients were similar with median values of 14.0 ng/mL [IQR, 9.9–19.3] and 14.4 ng/mL [IQR, 12.3–19.8] (\textit{P} = 0.132) in MRA-Neg and MRA-Plus, respectively (Table 1).

MRA-neg, Patients not treated by mineralocorticoid receptor antagonist; MRA-plus, Patients treated by mineralocorticoid receptor antagonist; AHT, arterial hypertension; ICM, ischemic cardiomyopathy; Creat: creatinine; LVEF, left ventricular ejection fraction; BNP, brain natriuretic peptide; Gal-3, Galectin-3; HR: heart rate; NYHA, New York Heart Association classes; SGOT, serum glutamic oxaloacetic transaminase; ARB II, angiotensin II receptor antagonists; AVK drugs, Anti vitamin K drugs; ACE inhibitors, angiotensin-converting-enzyme inhibitors. Propensity score was used to match patients based on the following variables: age, gender, obesity, diabetes, arterial hypertension (AHT), dyslipidemia, ischemic cardiomyopathy (ICM), left ventricular ejection fraction (LVEF), blood creatinine concentration (Creat). *Acute pulmonary edema occurring during the last month preceding the inclusion.

Median follow-up was 1.13 years (14 months) [IQR, 0.46–1.65 (6–20 months)]. Out of the 202 patients, 31 (15%) were censored for primary endpoint and 171 (85%) were end-of-study censored. The concentration of Gal-3 was higher in patients who died than in survivors with median values of 29.6 ng/mL [IQR, 14.8–33.1] and 13.8 ng/mL [IQR, 10.5–17.6] for the former and later, respectively, \textit{P}<0.001. Patients were stratified according to baseline Gal-3 concentration ≤ 17.8 ng/mL which corresponds to the cut off with the low risk of adverse outcome in HF patients \cite{8}. Out of the 202 patients, 140 (69%) had a Gal-3 concentration ≤ 17.8 ng/mL. Survival analysis showed that patients with a Gal-3 >17.8 ng/mL presented a higher risk of death with a HR of 7.42 [95%CI, 5.47–27.96] and a median survival time of 2.4 years [95%
CI, 1.8–2.4] (Fig. 1A). Similar HR values were obtained with univariate Cox proportional hazard analysis adjusted for age and gender (Table 2) or with different multivariate models which included clinical, paraclinical and medication factors (Table 3). Clearly, MRA treatment was not associated with survival of patients (Table 2). Indeed, the prognostic value of Gal-3 was not significantly affected by MRA treatment (Fig. 1B). Multivariate Cox proportional hazard analysis confirmed that MRA and the interaction term between MRA treatment and Gal-3 > 17.8 ng/mL were not factors associated with survival (see Model 4, Table 3).

| Table 1. Baseline characteristics of CHF patients. |
|-----------------------------------------------|
| MRA-Neg (n = 101) | MRA-Plus (n = 101) | P    |
|-------------------|------------------|------|
| Age, y ±SD        | 59 ± 15          | 57 ± 11 | 0.299 |
| Gender, % female  | 23               | 20    | 0.731 |
| Obesity, %        | 23               | 25    | 0.869 |
| Diabetes, %       | 23               | 22    | 1.000 |
| AHT, %            | 36               | 33    | 0.767 |
| Dyslipidemia, %   | 41               | 35    | 0.468 |
| ICM, %            | 41               | 41    | 0.886 |
| LVEF, % [95% CI]  | 30 [28–34]       | 30 [26–31] | 0.346 |
| LVEF < 30, %      | 41               | 46    | 0.571 |
| HR, bpm [95% CI]  | 70 [69–80]       | 72 [70–76] | 0.554 |
| NYHA 2            | 55               | 60    | 0.627 |
| NYHA 3            | 32               | 32    | 0.879 |
| NYHA 4            | 12               | 8     | 0.541 |
| ICM, %            | 41               | 41    | 0.886 |
| Acute pulmonary*  | 34               | 34    | 0.882 |
| ARA II            | 13               | 13    | 0.834 |
| Calcium blockers  | 7                | 7     | 0.782 |
| AVK drugs         | 34               | 35    | 0.961 |
| Antiplatelet Agents | 39         | 46    | 0.325 |
| Statines          | 49               | 44    | 0.572 |
| Beta blockers     | 67               | 86    | 0.003 |
| ACE inhibitors    | 60               | 80    | 0.003 |
| Furosemide        | 60               | 90    | <0.001 |
| Creat, μM [95% CI]| 95 [90–102]      | 97 [88–102] | 0.910 |
| Serum sodium, mM  | 139 [137–139]    | 137 [137–138] | 0.005 |
| SGOT, IU/l [95% CI]| 28 [25–32]  | 27 [25–30]    | 0.757 |
| BNP, pg/ml [95% CI]| 399 [210–206] | 364 [261–563] | 0.724 |
| Gal-3, ng/ml [95% CI]| 14.0 [9.9–19.3] | 14.4 [12.3–19.8] | 0.132 |

doi:10.1371/journal.pone.0119160.t001

CI, 1.8–2.4] (Fig. 1A). Similar HR values were obtained with univariate Cox proportional hazard analysis adjusted for age and gender (Table 2) or with different multivariate models which included clinical, paraclinical and medication factors (Table 3). Clearly, MRA treatment was not associated with survival of patients (Table 2). Indeed, the prognostic value of Gal-3 was not significantly affected by MRA treatment (Fig. 1B). Multivariate Cox proportional hazard analysis confirmed that MRA and the interaction term between MRA treatment and Gal-3 > 17.8 ng/mL were not factors associated with survival (see Model 4, Table 3).

HR value for Gal-3 > 17.8 ng/mL adjusted for age, gender and in model 1 (+ creat, BNP, serum sodium) or in model 2 (+ ARA II, Beta blockers, ACE inhibitors, Furosemide) or in model 3 (+ LVEF and HR). Model 4, HR value for Gal-3 > 17.8 ng/mL adjusted for age, gender, MRA and interaction term MRA * Gal-3 > 17.8 ng/mL (0.87 [95% CI, 0.37–2.05], p = 0.750 and 0.57 [95% CI, 0.13–3.07]). HR values for MRA and interaction term respectively. Model 5, HR values for Gal-3 > 17.8 ng/mL determined using stepwise method for selection of variables included in model 1 to 3.
Discussion

Our study confirms previous observations on the prognostic value of Gal-3 in patients with HF [27]. Our cohort consisted of HF patients with systolic HF, but even in patients with preserved ejection fraction Gal-3 was shown to be prognostic [28]. Moreover, Gal-3 changes in patients were shown to be a strong prognostic indicator [29]. In addition, Gal-3 levels have a potential role in early detection of myocardial structural and functional alterations [30] and risk stratification in HF [31, 32].

Since patients with low Gal-3 levels were shown to benefit from statin therapy [33], this observation suggested that Gal-3 levels could be used to predict response to therapies. Therefore, we assessed the influence of MRA treatment on the prognostic value of Gal-3. Clearly, in our cohort MRA treatment did not alter the prognostic value of Gal-3. We also observed that MRA treatment did not alter mortality in our cohort. Several clinical studies have proposed that MRA treatment reduced all-cause death in HF [34–37] but other studies failed to show a reduction in mortality [23, 38]. However, the positive studies were conducted in very large cohorts and the beneficial effect of MRA may not be observed in the later rather small cohorts. Fiuzat et al. have also investigated the relationship between Gal-3 levels and the use of MRA in HF.
Despite the fact that this was a much larger cohort, the authors did not show a significant difference in outcomes of patients on MRA, even after adjustment for important clinical variables. Accordingly, as observed in our study, the prognostic value of Gal-3 in this study was not impaired by MRA use. We believe that a prospective randomized multicentric study will be required to further investigate the possible interactions of MRA and Gal-3, and to draw final conclusions whether Gal-3 can be useful to select patients who will benefit from MRAs.

Table 2. Univariate Cox proportional hazards analysis.

|                         | HR [95% CI]       | P     |
|-------------------------|-------------------|-------|
| Age, per 10 y           | 1.24 [0.92–1.67]  | 0.156 |
| Gender, male = 1        | 0.51 [0.18–1.48]  | 0.224 |
| Obesity                 | 0.64 [0.25–1.66]  | 0.364 |
| Diabetes                | 1.28 [0.57–2.85]  | 0.547 |
| AHT                     | 1.55 [0.75–3.17]  | 0.233 |
| Dyslipidemia            | 0.90 [0.43–1.88]  | 0.786 |
| ICM                     | 1.42 [0.70–2.90]  | 0.331 |
| Acute pulmonary         | 1.48 [0.67–3.26]  | 0.342 |
| LVEF per 5%             | 0.82 [0.69–0.98]  | 0.029 |
| HR, per 5 unit          | 1.15 [1.04–1.26]  | 0.005 |
| MRA                     | 0.98 [0.48–1.98]  | 0.950 |
| ARA II                  | 0.19 [0.03–1.39]  | 0.103 |
| Calcium blockers        | 0.94 [0.22–4.02]  | 0.940 |
| AVK drugs               | 1.04 [0.49–2.21]  | 0.916 |
| Antiplatelet Agents     | 1.03 [0.50–2.09]  | 0.943 |
| Statines                | 0.71 [0.34–1.46]  | 0.355 |
| Beta blockers           | 0.35 [0.15–0.79]  | 0.002 |
| ACE inhibitors          | 0.51 [0.25–1.05]  | 0.070 |
| Furosemide              | 2.78 [1.28–6.03]  | 0.042 |
| Creatinine per 10 μM    | 1.11 [1.02–1.20]  | 0.013 |
| Serum sodium per mM     | 0.82 [0.76–0.87]  | <0.001 |
| BNP per 100 pg/ml       | 1.09 [1.05–1.13]  | <0.001 |
| Gal-3 > 17.8 ng/ml      | 7.25 [3.28–16.03] | <0.001 |
| Gal-3 per 10 ng/ml      | 2.45 [1.91–3.15]  | <0.001 |

* Hazard ratio adjusted for age and gender. In bold variables with p < 0.2 implemented in the multivariate Cox proportional hazards analysis.

Table 3. Multivariate Cox proportional hazards analysis.

| Model        | HR       | 95% CI      | P     |
|--------------|----------|-------------|-------|
| Model 1      | 4.75     | 1.99–11.36  | <0.001|
| Model 2      | 7.01     | 3.01–16.30  | <0.001|
| Model 3      | 6.07     | 2.62–14.02  | <0.001|
| Model 4      | 7.25     | 3.28–16.03  | <0.001|
| Model 5      | 5.75     | 1.97–16.81  | <0.001|

[23] Despite the fact that this was a much larger cohort, the authors did not show a significant difference in outcomes of patients on MRA, even after adjustment for important clinical variables. Accordingly, as observed in our study, the prognostic value of Gal-3 in this study was not impaired by MRA use. We believe that a prospective randomized multicentric study will be required to further investigate the possible interactions of MRA and Gal-3, and to draw final conclusions whether Gal-3 can be useful to select patients who will benefit from MRAs.
Study limitations
This study was retrospective and designed with the IBLOMAVED cohort. Despite the comparative groups were optimized with the use of the propensity score matching, the analysis was performed on a limited number of patients.

Conclusions
In our cohort of chronic stable systolic HF, baseline Gal-3 has a strong independent prognostic value irrespective of treatment with MRAs. The significance of the observed lack of an interaction between Gal-3 and treatment effect of MRAs remains to be elucidated.

Acknowledgments
We are grateful to bioMérieux (Marcy l’Etoile, France) for the supply of the VIDAS analyzer and reagents for Gal-3 measurement.

Author Contributions
Conceived and designed the experiments: FK FD MG FS PR. Performed the experiments: MG M. Barutaut CC ME M. Berry. Analyzed the data: FK FD MG FS PR. Contributed reagents/materials/analysis tools: FD MG GM. Wrote the paper: FK FD MG RD FS PR.

References
1. Barondes SH, Cooper DN, Gitt MA, Leffler H. Galectins. Structure and function of a large family of animal lectins. J Biol Chem. 1994; 269(33):20807–10. PMID: 8063682
2. Cooper DN. Galetcinomics: finding themes in complexity. Biochim Biophys Acta. 2002; 1572(2–3): 209–31. PMID: 12223284
3. Dumic J, Dabelic S, Flogel M. Galectin-3: an open-ended story. Biochim Biophys Acta. 2006; 1760-4):616–35. PMID: 16478649
4. Sharma UC, Pokhrel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004; 110(19):3121–8. PMID: 15520318
5. de Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009; 11(9):811–7. doi: 10.1093/eurjhf/hfp097 PMID: 19648160
6. van Kimmenade RR, Januzzi JL Jr, Ellinor PT, Sharma UC, Bakker JA, Low AF, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol. 2006; 48(6):1217–24. PMID: 16979009
7. de Boer RA, Lok DJ, Jaarsma T, van der Meer P, Voors AA, Hillege HL, et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med. 2011; 43(1):60–8. doi: 10.3109/07853890.2010.538080 PMID: 21189092
8. Lok DJ, Van Der Meer P, de la Porte PW, Lipiec E, Van Wijngaarden J, Hillege HL, et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol. 2010; 99(S):323–8. doi: 10.1007/s00392-010-0125-y PMID: 20130888
9. de Boer RA, van Veldhuisen DJ, Gansevoort RT, Muller Kobold AC, van Gilst WH, Hillege HL, et al. The fibrosis marker galectin-3 and outcome in the general population. J Intern Med. 2012; 272(1):55–64. doi: 10.1111/j.1365-2796.2011.02476.x PMID: 22026577
10. Ho JE, Liu C, Lyass A, Courchesne P, Pencina MJ, Vasas RS, et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J Am Coll Cardiol. 2012; 60(14):1249–56. doi: 10.1016/j.jacc.2012.04.053 PMID: 22939561
11. Yancy CW, Jessup M, Bozkurt B, Butler J, Case DF Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62(16):e147–239. doi: 10.1016/j.jacc.2013.05.019 PMID: 23747642
12. Gopal DM, Kommineni M, Ayallon N, Koebl C, Ayalon R, Biolo A, et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: effects of clinical status, pathophysiology of heart failure,
13. Lin YH, Lin LY, Wu YY, Chien KL, Lee CM, Hsu RB, et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta. 2009; 409(1–2):96–9. doi: 10.1016/j.cca.2009.09.015 PMID: 19758569

14. Yu L, Ruijtker WP, Meissner M, Bos EM, van Goor H, Sanjabi B, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013; 6(1):107–17. doi: 10.1161/CIRCHEARTFAILURE.112.971168 PMID: 23230309

15. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol. 2008; 172(2):288–98. doi: 10.2353/ajpath.2008.070726 PMID: 18202187

16. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A. 2006; 103(13):5060–5. PMID: 16549783

17. Mackinnon AC, Gibbons MA, Farnworth SL, Leffler H, Nilsson UJ, Delaine T, et al. Regulation of transforming growth factor-beta1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012; 185(5):537–46. doi: 10.1164/rccm.201106-0965OC PMID: 22095546

18. White PC. Aldosterone: direct effects on and production by the heart. J Clin Endocrinol Metab. 2003; 88(6):2376–83. PMID: 12788331

19. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, de Boer RA, et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol. 2013; 33(1):67–75. doi: 10.1161/ATvbaha.112.300569 PMID: 23117656

20. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012; 14(8):803–69. doi: 10.1036/eu/jhf/hsf105 PMID: 22828712

21. Brilla CG. Aldosterone and myocardial fibrosis in heart failure. Herz. 2000; 25(3):299–306. PMID: 10904856

22. Zannad F, Alla F, Doussset B, Perez A, Pitt B, et al. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000; 102(22):2700–6. PMID: 11094035

23. Fiuzat M, Schulte PJ, Felker M, Ahmad T, Neely M, Adams KF, et al. Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. J Card Fail. 2014; 20(1):38–44. doi: 10.1016/j.cardfail.2013.11.011 PMID: 24304938

24. Smith F, Desmoulin F, Berry M, Turkieh A, Harmancey R, Iacovoni J, et al. Blood signature of pre-heart failure: a microarrays study. PLoS One. 2011; 6(6):e20414. doi: 10.1371/journal.pone.0020414 PMID: 21731613

25. Ho D, Imai K, King G, Stuart E. Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference. Political Analysis. 2007; 15:199–236.

26. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011; 10(2):150–61. doi: 10.1002/pst.433 PMID: 20925139

27. McCullough PA, Olobatoke A, Vanhecke TE. Galectin-3: a novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med. 2011; 12(4):200–10. doi: 10.3909/rccm0624 PMID: 22249510

28. Carrasco-Sanchez FJ, Aramburu-Bodas O, Salamanca-Bautista P, Morales-Rull JL, Galisteo-Almeda L, Paez-Rubio MI, et al. Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction. Int J Cardiol. 2013; 169(3):177–82. doi: 10.1016/j.ijcard.2013.08.081 PMID: 24207066

29. van der Velde AR, Gullestad L, Ueland T, Aukrust P, Guo Y, Adourian A, et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail. 2013; 6(2):199–216. doi: 10.1161/CIRCHEARTFAILURE.112.000129 PMID: 23395934

30. Seferovic JP, Lalic NM, Floridi F, Tesic M, Seferovic PM, Giga V, et al. Structural myocardial alterations in diabetes and hypertension: the role of galectin-3. Clin Chem Lab Med. 2014; 52(10):1499–505. doi: 10.1515/cclm-2014-0265 PMID: 24887961

31. De Berardinis B, Magrini L, Zampini G, Zancia B, Salerno G, Cardelli P, et al. Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure. Biomed Res Int. 2014; 2014:983098. doi: 10.1155/2014/983098 PMID: 25101304
32. Peacock WF, DiSomma S. Emergency department use of galectin-3. Crit Pathw Cardiol. 2014; 13(2):73–7. doi: 10.1097/HPC.0000000000000012 PMID: 24827884

33. Gullestad L, Ueland T, Kjekshus J, Nymo SH, Hulthe J, Muntendam P, et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J. 2012; 33(18):2290–6. PMID: 22513778

34. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341(10):709–17. PMID: 10471456

35. Collier TJ, Pocock SJ, McMurray JJ, Zannad F, Krum H, van Veldhuisen DJ, et al. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Eur Heart J. 2013; 34(36):2823–9. doi: 10.1093/eurheartj/eht247 PMID: 23864130

36. Rossignol P, Menard J, Fay R, Gustafsson F, Pitt B, Zannad F. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol. 2011; 58(19):1958–66. doi: 10.1016/j.jacc.2011.04.049 PMID: 22032706

37. Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Minami K, et al. Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure. Int J Cardiol. 2013; 167(1):244–9. doi: 10.1016/j.ijcard.2011.12.080 PMID: 22245478

38. Hernandez AF, Mi X, Hammill BG, Hammill SC, Heidenreich PA, Masoudi FA, et al. Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. JAMA. 2012; 308(20):2097–107. doi: 10.1001/jama.2012.14795 PMID: 23188026